New Guidelines for Stage IV NSCLC Without Driver Alterations – Oncology Nurse Advisor
ASCO has released updated guidelines for the treatment of stage IV NSCLC without driver alterations.
ASCO has released updated guidelines for the treatment of stage IV NSCLC without driver alterations.
Welcome to our Elsevier’s Oncology Journal Network Highlights page
In an analysis of data from the PORTEC-1, -2, and -3 trials, older age was found to be associated with more aggressive tumor features and…
This marks the first Epstein-Barr virus-related mRNA therapeutic cancer vaccine to be approved by the FDA.
A 35-year-old South African woman, who was newly diagnosed with HIV after having started antiretroviral treatment 3 weeks prior, presented to a peripheral hospital with…
A list of current (APEx®) facilities.
Imatinib resistance at diagnosis was higher in cells of patients who relapsed vs those in remission after imatinib and chemotherapy.Low levels of BCR::ABL1
Sarah Wilder wanted a way to give back while her husband received treatment at MD Anderson for stage IV prostate cancer. A blood drive provided…
BackgroundSMARCA4, the essential ATPase subunit of SWI/SNF chromatin remodeling complex, regulates transcription through the control of chromatin structure a…
In this discussion chaired by Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The…
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.